Stock Ratings / Health Care / COAG / forecast

ALVO (58) VIR (31) MAZE (45) MESO (60) ⌘ Pro Terminal →

Hemab Therapeutics Holdings Inc. (COAG) 12-Month Stock Forecast & Price Target Cone

$40.42 +4.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.71

Hemab Therapeutics Holdings Inc. (COAG) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.89B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $40.71 (+0.71%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COAG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY COAG SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (23% of score)

FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 67.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$31.62-4.9% Next Q

Q2 (-2Q)

Grade C-$30.07+14.4% Next Q

Q3 (-1Q)

Grade C-$34.40+17.5% Next Q

Current

Grade D+$40.42-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the COAG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, COAG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.90) or 200D SMA ($36.78) invalidates the momentum regime and cuts Target Base ($40.24) toward Bear Floor ($31.39).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COAG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “COAG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your COAG Position Size: $10,000

Shares at $40.42: 247.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $31.39

$7,766

$-2,234 (-22.3%)

12M Consensus BaseTarget $40.24

$9,955

$-45 (-0.4%)

12M Bull Case BreakoutTarget $58.19

$14,396

+$4,396 (+44.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$42	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$55	69%	B
JP MorganUS Large-Cap Research	SELL	$36	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COAG)

✓Walkthrough of COAG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

COAG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.88%▲ RESISTANCE BREAKOUT

2026-10-30O $40.34H $42.85L $39.38C $40.42VOL 765.5K

RES: $29.22SUP: $28.10SMA50: $37.90SMA200: $36.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COAG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COAG Butterfly Map → + Track COAG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on COAG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COAG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for COAG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COAG)

Health Care Rank #251 of 1016 ⚔️ ALVO vs COAG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COAG vs. ALVO, VIR, MAZE, MESO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Hemab Therapeutics Holdings Inc. (COAG) ranks #251 by composite RQD confidence (57/100, grade D+) and #274 by equity capitalization ($1.89B). Within this direct 5-issuer industry benchmark cohort, COAG leads on earnings valuation at N/A trailing P/E, while VIR leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. MESO currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with COAG at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
COAG ACTIVE Hemab Therapeutics Holdings Inc.	D+	57/100	—	—	—	+4.99%	$1.89B	Benchmark Subject
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-coag →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-coag →
MAZE Maze Therapeutics Inc.	D	45/100	—	—	-35.0%	+0.63%	$1.77B	/maze-vs-coag →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-coag →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002114044

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hemab Therapeutics Holdings Inc. (COAG) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, COAG closed FY2025 with $194.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$194.8M	—

3. COAG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COAG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $40.42 (+4.99% 1D, market cap $1.89B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, COAG ranks #251 in composite RQD confidence.

How does COAG compare to ALVO and VIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), COAG carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALVO (Alvotech) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.91B) and VIR (Vir Biotechnology Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.01B). Among the 5-stock peer group, COAG leads on earnings multiple (N/A) while VIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COAG?

Per COAG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002114044), Hemab Therapeutics Holdings Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $194.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COAG trading relative to its 50-day, 200-day, and 52-week technical levels?

COAG last traded at $40.42 (+4.99% on volume of 1,195,923 shares), positioning the stock +6.65% above its 50-day simple moving average ($37.90) and +9.90% above its 200-day simple moving average ($36.78). Across its 52-week range of $23.00 to $55.42, COAG sits at the 53.7% percentile with a 14-day RSI of 67.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($35.37 to $45.47).

COAG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is COAG's 12-month stock price target?

Hemab Therapeutics Holdings Inc. (COAG) carries a 12-month consensus base price target of $40.24 (-0.4% from $40.42), with a bull-case target of $58.19 and a bear-case floor of $31.39.

Is COAG stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates COAG D+ (Sell — SELL) with an RQD Confidence score of 57/100.

Direct Sub-Reports: COAG RQD Cockpit COAG 12M Forecast COAG Earnings & Move COAG Dividends & DRIP COAG Insiders & 13F COAG Whale Options COAG Profit Sankey COAG News & Why